Visp/Viège

Visp/Viège

Visp r j s paaugstin tas jut bas reakcijas var b t dz v bai b stamas.
http://www.emea.europa.eu/

Generalised hypersensitivity reactions are potentially life threatening.
http://www.emea.europa.eu/

Kl nisko p t jumu laik hipoglik mijas visp r jais biežums neatš r s pacientiem, kuri tika rst ti ar asparta insul nu un cilv ka insul nu.
http://www.emea.europa.eu/

In clinical trials and during marketed use the frequency varies with patient population and dose
http://www.emea.europa.eu/

Konsult jieties ar savu rstu vai j s visp r varat vad t transportl dzekli vai apkalpot meh nismus, ja jums bieži rodas hipoglik mijas vai, ja hipoglik mijas ir gr ti atpaz t.
http://www.emea.europa.eu/

Discuss with your doctor whether you should drive or use machines at all, if you have a lot of hypos or if you find it hard to recognise hypos.
http://www.emea.europa.eu/

Visp r jas paaugstin tas jut bas simptomi var b t eneraliz ti das izsitumi, nieze, sv šana, gastrointestin li trauc jumi, angioneirotiska t ska, apgr tin ta elpošana, pa trin ta sirdsdarb ba un asinsspiediena pazemin šan s.
http://www.emea.europa.eu/

Very rare - Anaphylactic reactions Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.
http://www.emea.europa.eu/

Visp r j s paaugstin tas jut bas reakcijas var b t potenci li b stamas dz v bai.
http://www.emea.europa.eu/

Generalised hypersensitivity reactions are potentially life threatening.
http://www.emea.europa.eu/

Kl nisko p t jumu laik hipoglik mijas visp r jais biežums neatš r s pacientiem, kuri tika rst ti ar asparta insul nu un cilv ka insul nu.
http://www.emea.europa.eu/

During clinical trials the overall rates of hypoglycaemia did not differ between patients treated with insulin aspart compared to human insulin.
http://www.emea.europa.eu/

Visp r jas paaugstin tas jut bas simptomi var b t eneraliz ti das izsitumi, nieze, sv šana, gastrointestin li trauc jumi, angioneirotiska t ska, apgr tin ta elpošana, pa trin ta sirdsdarb ba, asinsspiediena pazemin šan s un bonis/ sama as zudums.
http://www.emea.europa.eu/

40 Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation, reduction in blood pressure and fainting/ loss of consciousness.
http://www.emea.europa.eu/

Šaj lietošanas instrukcij ir visp r ja inform cija.
http://www.emea.europa.eu/

This leaflet is a general guide.
http://www.emea.europa.eu/

Vesel bas apr pes speci listiem, radiniekiem un citiem apr p t jiem j iev ro visp r jie piesardz bas pas kumi, no emot un likvid jot adatas, lai nov rstu nejaušas saduršan s risku.
http://www.emea.europa.eu/

Health care professionals, relatives and other carers must follow general precautionary measures for removal and disposal of needles to eliminate the risk of unintended needle penetration.
http://www.emea.europa.eu/

Vispā ji traucē
http://www.emea.europa.eu/

INFORMATION IN BRAILLE
http://www.emea.europa.eu/

Visp r ji trauc jumi un reakcijas ievad šanas viet Reti: perif ra t ska Izmekl jumi oti reti:
http://www.emea.europa.eu/

Increased blood pressure Nervous system disorders Very rare:
http://www.emea.europa.eu/

Visp r g ietekme uz CNS T k olanzap nam ir prim ra ietekme uz CNS, j iev ro piesardz ba, ja to lieto kombin cij ar citiem centr las darb bas l dzek iem un alkoholu.
http://www.emea.europa.eu/

General CNS activity Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting medicines and alcohol.
http://www.emea.europa.eu/

Visp r ga ietekme uz CNS Piesardz ba j iev ro pacientiem, kas lieto alkoholu vai medikamentus, kuri izraisa centr l s nervu sist mas nom kumu.
http://www.emea.europa.eu/

General CNS activity Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.
http://www.emea.europa.eu/

Skeleta- musku u un saistaudu sist mas boj jumi Rabdomiol ze Nieru un ur nce u trauc jumi Ur na aizture Reprodukt v s sist mas un kr ts slim bas Priapisms Visp r ji trauc jumi un reakcijas ievad šanas viet Ast nija Nogurums T ska Izmekl jumi Paaugstin ts proakt na l menis plazm 8 1
http://www.emea.europa.eu/

Musculoskeletal and connective tissue disorders Rhabdomyolysis Renal and urinary disorders Urinary hesitation Reproductive system and breast disorders Priapism General disorders and administration site conditions Asthenia Fatigue Oedema Investigations Elevated plasma prolactin levels8 1
http://www.emea.europa.eu/

Tom r vecuma, dzimuma un sm šanas ietekmes uz olanzap na kl rensu un elimin cijas pusperiodu noz m gums ir niec gs, sal dzinot ar visp r j m individu l m atš ir b m pacientu vid.
http://www.emea.europa.eu/

However, the magnitude of the impact of age, gender, or smoking on olanzapine clearance and half-life is small in comparison to the overall variability between individuals.
http://www.emea.europa.eu/

Visp r ji trauc jumi un reakcijas ievad šanas viet Ret k - reakcijas injekcijas viet. es
http://www.emea.europa.eu/

General disorders and administration site conditions Uncommon - Injection site reactions a
http://www.emea.europa.eu/

Šie faktori ir j em v r visp r j to pacientu rst šan, kuriem var tu noz m t Vaniqa.
http://www.emea.europa.eu/

These factors should be considered in the overall medical treatment of patients who might be prescribed Vaniqa.
http://www.emea.europa.eu/

P t juma RUTH sekund rais m r a parametrs bija visp r g s inform cijas par kl niskiem l zumiem v kšana.
http://www.emea.europa.eu/

In the RUTH study overall clinical fractures were collected as a secondary endpoint.
http://www.emea.europa.eu/

S– albumīns (g/ dl)
http://www.emea.europa.eu/

S-Albumin (g/ dl)
http://www.emea.europa.eu/